Background {#Sec1}
==========

Mechanical cardiopulmonary assistance, which is often utilized as an integral part of certain invasive cardiac surgeries, is increasingly used in resuscitation of patients in intensive care settings and emergency departments \[[@CR1]--[@CR12]\]. Prolonged cardiopulmonary assistance is called extracorporeal membrane oxygenation (ECMO) or extracorporeal life support (ECLS) and is a sophisticated and resource-intensive intervention for critically ill patients with cardiac or respiratory dysfunction \[[@CR11], [@CR12]\]. ECMO and ECLS are often used interchangeably \[[@CR13]\].

There are two types of ECMO -- veno-venous (VV) and veno-arterial (VA) ECMO -- depending on differences in vascular access. During VV ECMO, blood is extracted from the vena cava or right atrium and returned oxygenated to the right atrium. During VA ECMO, blood is extracted from the right atrium and returned oxygenated to the arterial system, most commonly the iliac artery. VA ECMO provides hemodynamic support in addition to respiratory support \[[@CR11]\].

Although ECMO use is more commonly described in the pediatric population, ECMO use in adults for cardiac and respiratory indications more recently became the largest contributing group in the Extracorporeal Life Support Organization Registry, which was established to improve quality and outcome of ECMO use \[[@CR4], [@CR12]\]. ECMO is used for various cardiac or pulmonary diseases including: post-cardiotomy, myocarditis, acute coronary syndrome or refractory cardiac arrest, as a bridge to heart/lung transplant, cardiogenic shock, respiratory failure, trauma/drowning as well as other conditions \[[@CR14]\]. In 2015, cardiogenic shock was found to be the most common diagnosis associated with ECLS use in adults with VA ECMO, occurring in 60.7% of such patients \[[@CR4]\]. Cardiogenic shock is a clinical condition of inadequate tissue perfusion due to cardiac dysfunction that is associated with persistent hypotension and end organ damage. Cardiogenic shock often results from myocardial infarction but can also result from other cardiac diseases such as myocarditis, pericarditis, and cardiomyopathy \[[@CR15]\].

ECMO use improves survival in patients with cardiac disease with survival rates ranging from 20 to 50% \[[@CR1]--[@CR10]\]. ECMO also increases 30-day survival rates when used to bridge patients in cardiogenic shock to coronary intervention procedures \[[@CR16]\]. Additionally, ECMO improves outcomes in patients with cardiac arrests -- mainly survival without neurologic deficit -- when added to cardiopulmonary resuscitation (CPR) \[[@CR3], [@CR17]\].

Contraindications for VA ECMO in cardiac failure do exist and include the following: ethical considerations and patient's will, no bridging goal, severe aortic regurgitation, aortic dissection, severe peripheral artery disease (iliac), left ventricular thrombus (relative contraindication) \[[@CR18]\]. Despite several observational and registry studies on ECMO use, few studies describe the extent of ECMO use in patients with cardiogenic shock. This study examines cardiogenic shock presentations that involved ECMO use and identifies variables associated with mortality in this U.S. hospital population sample.

Methods {#Sec2}
=======

Data and materials {#Sec3}
------------------

NEDS is a product of Healthcare Cost and Utilization Project (HCUP) under the auspices of the Agency for Healthcare Research and Quality (AHRQ) \[[@CR19]\]. It is the largest U.S. all-payer ED database, combining medical and non-clinical data from both national and state sources. Data from this stratified sample is accrued from 945 hospital-owned EDs located across 30 States and the District of Columbia, reflecting approximately 20% of all hospital-based EDs located in the United States. The following stratification variables were used to weight data per HCUP specifications: U.S. Census region, urban-rural location, ownership, and teaching status of the hospital as well as trauma center designation \[[@CR20]\]. This stratified sample of patients is statistically weighted using the above stratification variables to approximate and examine national estimates. Weighting of sample compensates for different probabilities of selection as part of the dataset sample. As per requirements for publishing HCUP data and to safeguard patients' privacy, data on any variable with size less than or equal to 10 are excluded.

Study design and population {#Sec4}
---------------------------

This retrospective study used the 2013 public release dataset of the US Nationwide Emergency Department Sample (NEDS) database. The 2013 NEDS dataset contains information on weighted 134,869,015 ED visits. Patients were included in this study if they met the following criteria: Adult patients (age 18 or older) who presented with cardiogenic shock and underwent ECMO procedure and died in the ED or were admitted to the same hospital during the selected visit.

Data definitions {#Sec5}
----------------

The NEDS data elements include: demographic patient information; mechanism, intent, and severity of injury; admission and discharge status; payment source; healthcare expenses and general hospital characteristics. The AHRQ Clinical Classifications Software (CCS) was used to select all patients with cardiogenic shock. CCS is a tool for grouping patient diagnoses and procedures into a convenient number of clinically meaningful categories similar and equivalent to than the International Classification of Diseases (ICD) coding system.

The following CSS codes are specific for cardiogenic shock: CCS 97, CCS 100, CCS 101, CCS 103, CCS 106, CCS 107, CCS 108 \[[@CR12]\]. A list of Equivalent ICD-9 CM codes and variable classification is included (See attachment, Additional File [1](#MOESM1){ref-type="media"} which illustrates code and variable classifications). Additionally, the ICD-9 CM procedure code 39.65 was used to gather all patients who underwent ECMO procedure.

Chronic diseases and procedures with frequencies less than 10% were removed from the analysis and were not displayed results. Injury severity score (ISS) is considered as the gold standard trauma severity score to predict morbidity, increased hospital stay and mortality in trauma patients. An ISS score greater than 15 is historically used as a cutoff value for severe trauma injury \[[@CR21]\]. This study used a more conservative cut off value for ISS of \> 8 since very few patients had an ISS score greater than 15. Previous studies have also shown that increasing injury severity (ISS of \> 8) is associated with increased hospital stay and ICU admission \[[@CR22]\].

AHRQ provides a database and a software tool, called the Chronic Condition Indicator (CCI), that allows for the identification of chronic diseases using ICD-9 CM coding. CCI was utilized in this study for the purposes of investigating presence of chronic conditions according to body system categories affected. According to CCI, the definition of a chronic disease is "a medical condition which lasts for twelve months or longer with either one of the following criteria being met: (1) the medical condition restricts self-care, independent living, and social interaction; (2) the medical condition results in the need of ongoing medical intervention."

Additionally, NEDS categorizes ICD-9 CM procedure codes into four broad categories labeled as either major or minor and therapeutic or diagnostic. An ICD-9 CM procedure is classified as "minor if the procedure is a non-operating room procedure and major if the procedure is a valid operating room procedure by the Diagnosis Related Group (DRG) grouper" (an ICD-9 CM grouping system). CCS procedure codes were also used to examine most common procedures other than ECMO.

Statistical analysis {#Sec6}
--------------------

IBM-SPSS 24 was used to carry out descriptive analysis on the socio-demographic, clinical and hospital characteristics. Mean with associated 95% confidence intervals (CI) was used for continuous variables, while frequencies, percentages and 95% CI were used for categorical variables.

The standard statistical methods that treat the data as being emerged from a simple random sampling data were inappropriate for the NEDS survey design and would yield biased estimates, overly-narrow confidence levels and misleading significance tests due to the type I error generated from the biased results. The Rao-Scott chi-square test, a modified version of the Pearson's chi-square test, as well as a general linear model (GLM) for complex sampling (CS) were used to assess the significance of the statistical association of the independent categorical and continuous variables respectively between the two groups (those who survived and those who did not). Logistic regression was conducted to identify significant associations with mortality in ECMO patients with cardiogenic shock. Variables that were significantly different between the two groups when compared by outcome (mortality) were included in the multivariate analysis.

All estimates (means, percentages, odds ratio and confidence intervals) were drawn by complex sampling methods, particularly, CSTABULATE, CSDESCRIPTIVES, CSGLM and CSLOGISTIC to adjust for the NEDS survey design and to ensure the results are accurate. CSTABULATE is a complex sample procedure that produces analysis for categorical variables. CSDESCRIPTIVES and CSGLM are two different complex sample procedures that allow for analysis of continuous variables at the univariate and bivariate levels respectively. Lastly, the Complex Samples Logistic Regression procedure, CSLOGISTIC, performs logistic regression for samples drawn by complex sampling methods.

Complex sampling design of the study resulted in decimal places among sample frequencies. To avoid rounding errors and for the sake of clarity, variables were restored to discrete format by discarding decimals. In addition, a maximal value for total sample frequency was capped at 992 patients. Analysis was verified using *HCUPnet*, a free on-line query system based on data from HCUP \[[@CR23]\]. Lastly, a *p*-value of \< 0.05 was used to indicate statistical significance.

Results {#Sec7}
=======

A total of 8,605,807 weighted adult visits were admitted to the emergency department with cardiogenic shock. Of those, 992 weighted adult patient visits included an ECMO procedure yielding a rate of 0.1 per 1000 ED visits for cardiogenic shock.

The mean age of the study population was 50.8 years (95%CI 48.8--52.7). Patients were more commonly males (66.3%; 95%CI 60.3--71.8). Visits were equally distributed across all four seasons and were mainly during the weekday (Monday through Friday) (70.6%, *n* = 700). Over half of visits were to large metropolitan hospitals (fringe 39.4%, *n* = 389 and central 29.1%, *n* = 287). Private insurance (47.8%, *n* = 472) as well as Medicare and Medicaid (43.6%, *n* = 430) were the most common primary expected payer types. (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of Study PopulationContinuous VariablesRangeMedian (IQR)Mean (95% CI)Age (years)18--9054 (23)50.8\
(48.8--52.7)*Categorical VariablesCount (N = 992)Percent (95% CI)*Gender (male)65866.3 (60.3--71.8)Median household income^*a*^ \$1 - \$37,99912613.2 (9.8--17.6) \$38,000 - \$47,99923825.1 (19.9--31.0) \$48,000 - \$63,99923825.0 (20.2--30.7) \$64,000 or more34836.7 (31.1--42.6)Season of admission Winter22323.2 (18.3--29.0) Spring24425.4 (20.5--31.0) Summer25927.0 (21.8--33.0) Autumn23424.3 (19.5--29.9)Admission day Monday - Friday70070.6 (64.7--75.8) Saturday - Sunday29229.4 (24.2--35.3)Patient location^b^ Large central metropolitan28729.1 (24.4--34.3) Large fringe metropolitan38939.4 (34.5--44.5) Medium metropolitan14714.9 (11.5--19.0) Small metropolitan666.6 (4.1--10.7) Micropolitan515.1 (3.2--8.1) Not metropolitan or micropolitan484.9 (3.0--7.9)Primary expected payer Private insurance47247.8 (41.6--54.1) Medicare & Medicaid43043.6 (37.3--50.1) Self-pay606.1 (3.8--9.7) Other252.5 (1.1--5.5)^a^According to national quartile for patient ZIP code derived from ZIP Code-demographic data obtained from Claritas^b^According to National Center for Health Statistics (NCHS) Urban-rural code

All patients had diseases of the circulatory system, and most patients had diseases of the respiratory system (82.7%, *n* = 820) as well as endocrine, nutritional, and metabolic diseases/immunity disorders (80.1%, *n* = 795) (Table [2](#Tab2){ref-type="table"}). Few patients had injury diagnosis reported on record (14.2%, *n* = 141). The most frequent injury reported was suffocation injury (1.9%, *n* = 19) followed by falling injury (1.5%, *n* = 15). Only 5.3% (*n* = 52) had increased injury severity defined by an ISS of 9 or greater. The mean for total charges (both ED and inpatient services) was \$589,610.5 (95% CI 512,270.0 -- 666,950.9). The mean hospital length of stay was 21.8 days (95% CI 19.0--24.6).Table 2Chronic Conditions, Injuries, and Outcomes of Sample PatientsCategorical VariablesCount (*N* = 992)Percent (95% CI)Chronic conditions body system indicator Circulatory system992100 Respiratory system82082.7 (77.5--86.9) Endocrine/nutritional/metabolic/immunity79580.1 (74.7--84.6) Symptoms, signs, and ill-defined conditions77978.5 (73.1--83.1) Genitourinary system72472.9 (67.1--78.1) Blood and blood-forming organs63664.1 (58.0--69.7) Injury and poisoning61762.2 (56.3--67.7) Digestive system41441.8 (35.8--47.9) Infectious and parasitic disease39339.7 (33.7--45.9) Health status/contact with health services factors38338.6 (33.1--44.4) Nervous system and sense organs31331.5 (26.1--37.5) Mental disorders18618.8 (14.3--24.2)Injury diagnosis reported on record No injury diagnoses reported85185.8 (80.8--89.7) Injury is reported14114.2 (10.3--19.2)Injuries Specified by the NEDS Database Injury by suffocation191.9 (0.8--4.4) Injury by falling151.5 (0.5--4.1)More than one injury diagnosis One or no injury diagnosis reported93894.5 (90.9--96.7) More than one injury diagnosis545.5 (3.3--9.1)Unintentional injury indicated Intention not specified92493.1 (89.2--95.6) Unintentional injury686.9 (4.4--10.8)Injury severity score^a^90.3 (85.9--93.5) No injury severity score8964.4 (2.4--7.8) 1--8445.3 (3.0--9.0) 9--7552Disposition of patient Admitted to same hospital992100 Survival to discharge50651.0 (44.8--57.1) Died in the ED/hospital48649.0 (42.9--55.2)Continuous VariablesFrequencyRangeMedian (IQR)Mean (95% CI)Total charges^b^ (USD\$)9883773--4,292,990409,138 (468,598)589,610.5 (512,270.0 -- 666,950.9)Length of stay (days)9920--13116 (24)21.8 (19.0--24.7)^a^Assigned by ICPIC Stata program^b^Total charges are for accumulated ED and Inpatient services

In addition to ECMO, patients with cardiogenic shock underwent different types of procedures (Table [3](#Tab3){ref-type="table"}). By procedure class, all patients had major therapeutic procedures on record since ECMO procedure is categorized as major therapeutic. Most patients (89.1%, *n* = 884) also had minor therapeutic procedures. The most common procedure other than ECMO was respiratory intubation and mechanical ventilation (56.7%, *n* = 562).Table 3Extracorporeal Membrane Oxygenation Among Cardiogenic Shock: ProceduresProcedure class for inpatientCount (*N* = 992)Percent (95% CI) Minor diagnostic53453.8 (47.8--59.7) Minor therapeutic88489.1 (84.6--92.4) Major diagnostic626.2 (3.8--10.1) Major therapeutic992100Specific procedures using CCS codesCount (*N* = 992)Percent (95% CI) Circulator system procedures  Extracorporeal circulation auxiliary to open heart procedures^a^992100  Other operating room heart procedures^b^51051.4 (45.3--57.5)  Diagnostic cardiac catheterization; coronary arteriography23123.3 (18.6--28.9)  Conversion of cardiac rhythm18318.4 (14.4--23.3)  Heart valve procedures17918.1 (13.9--23.1)  Coronary artery bypass graft (CABG)15015.1 (11.5--19.6)  Other non-operating room therapeutic cardiovascular procedures12312.4 (9.0--16.9)  Percutaneous transluminal coronary angioplasty (PTCA)11311.4 (8.1--15.8)  Echocardiogram10710.8 (7.6--15.3)  Swan-Ganz catheterization for monitoring10210.2 (7.2--14.4)  Blood transfusion22022.2 (17.9--27.2) Respiratory system procedures  Respiratory intubation and mechanical ventilation56256.7 (50.5--62.7)  Other operating room procedures on respiratory system and mediastinum18218.4 (14.0--23.7)  Diagnostic bronchoscopy and biopsy of bronchus13513.6 (10.0--18.3)  Tracheostomy; temporary and permanent11111.2 (7.8--15.9) Other procedures  Other operating room procedures^b^36536.8 (31.1--42.9)  Other vascular catheterization; not heart33033.3 (27.8--39.3)  Other therapeutic procedures^c^20720.9 (16.5--26.1)^a^This CCS procedure code also includes ICD-9 procedure code 39.65 for ECMO procedures^b^Examples include operations on valves and septa of the heart, heart vessels, and the heart and pericardium^c^Specifically procedures on vessels other than head/neck^d^Nervous, ophthalmic, gastrointestinal procedures not otherwise specified

For Patients who underwent ECMO, there were significant differences between those who survived to hospital discharge and those who did not. Table [4](#Tab4){ref-type="table"} lists only the statistically significant variables between the two groups and which included age, season of admission, presence of certain chronic conditions and certain procedures, whether injury was reported, total charges, and length of stay (LOS). Those who survived were slightly younger than those who did not (49.5 vs 52.1, years respectively *p* = 0.009) and had significantly higher total hospital charges for services as well as total length of stay.Table 4Comparison of Study Groups Stratified by Outcome (Mortality)Survival to Discharge\
(*N* = 506)Mortality\
(*N* = 486)Categorical Variables^a^CountPercent (95% CI)CountPercent (95% CI)*p*-valueSeason of admission Winter8517.4 (11.7--25.2)13829.2 (21.8--37.8)0.006 Spring10421.3 (15.0--29.1)14029.7 (22.2--38.5) Summer14028.7 (21.3--37.5)11925.2 (18.2--34.0) Autumn15932.6 (25.6--40.3)7515.9 (10.3--23.7)Chronic conditions506100487100 Respiratory system38976.9 (69.1--83.2)43188.6 (81.4--93.3)0.014 Injury and poisoning37574.2 (65.9--81.0)24249.7 (41.1--58.3)\< 0.001 Genitourinary system30560.4 (51.7--68.4)41986.0 (79.6--90.7)\< 0.001 Digestive system17835.3 (27.5--43.9)23648.5 (39.8--57.3)0.034 Nervous system & sense organs12725.1 (18.4--33.4)18638.2 (30.1--46.9)0.025Injury diagnosis No injury diagnoses39277.7 (69.3--84.3)45994.3 (88.7--97.2)\< 0.001 Injury is reported11322.3 (15.7--30.7)285.7 (2.8--11.3)*Procedures* Other operating room procedures^b^22544.5 (36.0--53.3)14028.8 (21.4--37.6)0.012 Tracheostomy^c^8216.1 (10.5--23.9)306.1 (3.0--12.1)0.015 Echocardiogram367.1 (3.8--12.9)7114.7 (9.5--22.0)0.05Continuous Variables^d^CountMean (95% CI)CountMean (95% CI)*p*-valueAge (years)50649.5 (46.8--52.1)48752.1 (49.3--54.9)0.009Total charges^e^ (USD)501695,089.0 (560,971.1-829,206.8)487480,927.5 (398,015.8-563,839.2)\< 0.001Length of stay (days)50628.8 (24.4--33.1)48714.6 (11.5--17.6)\< 0.001^a^The *p*-values for the categorical variables were calculated using the Rao-Scott chi-square test of the complex sample procedure^b^Specifically procedures on vessels other than head and neck^c^Temporary and permanent^d^The *p*-values for the continuous variables were calculated using the general linear model of the complex sample procedure^e^Total charges are for accumulated ED and Inpatient services

Table [5](#Tab5){ref-type="table"} shows the variables associated with mortality in ECMO patients. Having diseases of either the respiratory system (OR = 3.83, 95%CI 1.76--8.31) or genitourinary system (OR = 4.97, 95%CI 2.39--10.33) as well as undergoing an echocardiogram (OR = 4.63, 95%CI 1.300--16.504) were significantly associated with increased mortality. Higher mortality was also associated with visits during all seasons when compared to autumn.Table 5Mortality with ECMO use in Cardiogenic Shock^a^Odds Ratio95% CI*p*-valueCCI^b^ - Nervous system and sense organs diseases1.220.64--2.320.541CCI - Respiratory system diseases3.831.76--8.310.001CCI - Digestive system diseases1.720.82--3.610.150CCI - Genitourinary system diseases4.972.39--10.33\< 0.001CCI - Injury and poisoning0.470.24--0.940.032Injury diagnosis reported0.450.15--1.360.156Tracheostomy; temporary and permanent0.460.14--1.480.190Other operating room procedures^c^0.490.24--1.000.048Echocardiogram4.631.30--16.500.018Season of admission (Autumn) Winter8.853.39--23.11\< 0.001 Spring5.442.16--13.73\< 0.001 Summer4.021.54--10.460.005Age (1 year)1.011.00--1.040.239Length of Stay (1 day)0.940.90--0.980.003Total charges^d^ (per \$10,000)1.011.00--1.020.069^a^Variables included in the model are: significant chronic conditions and procedures found at the bivariate level, injury diagnosis, season of admission, age, and total charges^b^CCI denotes body system categories affected by chronic conditions^c^Specifically procedures on vessels other than head and neck^d^Total charges are for accumulated ED and Inpatient services

Conversely, having a chronic disease of injury and poisoning (OR = 0.382, 95%CI 0.191--0.765), undergoing other operating room procedures on vessels other than head and neck (OR = 0.49, 95%CI 0.24--1.00), as well as increasing total charges (OR = 0.993 95%CI 0.988--0.999) were associated with decreased mortality.

Discussion {#Sec8}
==========

ECMO use is increasing in adult patients with cardiogenic shock, but few studies that describe ECMO use or associations with mortality in this population are available. This study is the first to use the largest US ED database, NEDS, to describe socio-demographic, clinical, and hospital characteristics for patients with cardiogenic shock who underwent ECMO.

This study also described patterns of ECMO use and outcomes of patients with cardiogenic shock. ECMO was used in 0.1 per 1000 ED/hospital visits with cardiogenic shock in 2013. Survival to hospital discharge was 51%. This finding is consistent with survival rates from previous studies that range from 20 to 50% \[[@CR1]--[@CR10]\].

The mean age of patients who presented to US EDs with cardiogenic shock and who underwent ECMO was 50.8 years (95%CI 48.4--52.7). Previous studies have shown similar characteristics \[[@CR12], [@CR24]\]. Maxwell et al. examined national ECMO use between the years 1998 to 2009 and found an overall mean age of 53.9 ± 0.4 years and a mean age of 48.9 ± 0.8 years among those with cardiogenic shock specifically \[[@CR12]\]. Schmidt et al., on the other hand, analyzed ECMO use only for refractory cardiogenic shock between the years of 2003 and 2013 and found a mean age of 54 years (range 39--64) \[[@CR24]\].

ECMO use as expected was mostly in large metropolitan hospitals. ECMO is considered a complex procedure and is fraught with complications such as stroke, neurologic complications, lower extremity ischemia, fasciotomy or compartment syndrome, amputation, acute kidney injury, renal replacement therapy, significant infection, major or significant bleeding and re-thoracotomy for bleeding or tamponade \[[@CR14], [@CR18]\]. Thus, it is usually reserved for when conventional treatments have failed and is usually undertaken in larger specialized centers.

Seasonal variation in mortality among patients presenting with cardiogenic shock and undergoing ECMO procedure was also identified in this study. The association of seasonal patterns on both hospital admission and mortality has been previously examined and described among patients with cardiovascular disease. Previous studies have reported increased adverse effects (hospital admission and mortality) during colder months (up to 10--20% increased mortality) \[[@CR25]--[@CR27]\]. Similarly, our study shows that the winter season was associated with the highest mortality (OR: 8.85; 95%CI: 3.39--23.11). Reasons for these seasonal variations though not directly identified in our study are multiple and complex, involving both physiologic and behavioral causes. Previously identified causes include sudden cold acclimatization, change in dietary patters, change in physical activity, changes in mental health, vitamin D deficiency, increased air pollution, and increased incidence of infectious disease \[[@CR26]\].

This study also identified variables associated with mortality in patients with cardiogenic shock requiring ECMO. In addition to previously described associated clinical variables, the study examined different socioeconomic and system level factors that might be affecting mortality in this population. Patients with specific chronic conditions such as diseases of the respiratory system or the genitourinary system were more likely to die. This was expected given that patients with multiple organ dysfunction syndrome require ventilator support or dialysis and are more likely to die. These findings are similar to previous studies where pre-ECMO predictive survival score (SAVE-score) in patients with refractory cardiogenic shock identified chronic renal failure as risk factor associated with mortality \[[@CR24]\].

The study also examined the costs and impact associated with ECMO use. The mean total charges for cardiogenic shock visits with ECMO procedure was \$589,610.5 (95%CI \$512,270.0 -- \$666,950.9) per admission. This mean is more than 10 times the national mean cost of patients with cardiogenic shock post ST-Elevation Myocardial Infarction in 2010 (\$45,625) \[[@CR28]\]. The mean length of stay for the study population was 21.8 days (95%CI 19.0--24.7). Both the mean cost and mean length of stay are higher than what Maxwell et al. previously reported on resource use trends in ECMO between 1998 and 2009 where the mean total hospital charges was \$344,009 ± \$30,707 per admission and the mean length of stay was 18.3 ± 1.3 days \[[@CR12]\]. Resources utilization with ECMO seem to be increasing without an associated increase in survival benefit. Future research is therefore needed to document trends in survival and the impact of ECMO use on outcomes of patients suffering from cardiogenic shock and from other conditions. ECMO is just one of several mechanical assist devices used in cardiogenic shock. Other devices include intra-aortic balloon pumps (IABP) and LV assist devices (LVADs). ECMO however, is the only intervention that compensates for both the right and left heart function as well as lung function. As such, ECMO decreases requirements for catecholamine, vasodilator, and mechanical ventilation in the treatment of cardiogenic shock and reduces the complications that are usually associated with these treatment modalities \[[@CR18], [@CR29]\]. ECMO use therefore holds promise for use in selected cardiogenic shock patients and further prospective studies are recommended.

The limitations of this study are directly related to structural features of the NEDS database. First, ICD-9 CM codes do not differentiate between VA or VV ECMO. This may be resolved with future use of ICD-10 CM codes. Second, information on the duration of ECMO use or timing of initiation is not available and costs are allocated to the whole hospital admission and not to a specific resource. Other limitations are related to the retrospective nature of the study. The quality and quantity of the data depends on the knowledge and experience of the coder, the completeness and accuracy of the patient record, and the state requirements. The study findings portray however trends in ECMO use for cardiogenic shock from a large sample from US based hospitals and can be generalized to other hospitals from similar settings.

Conclusion {#Sec9}
==========

Mortality in adult patients with cardiogenic shock remains high despite ECMO use. Season of admission (other than Fall) and presence of specific comorbidities (Respiratory and genitourinary diseases) are associated with increased mortality in this population. Familiarity with patients' characteristics and variables associated with mortality after ECMO use is important to improve outcomes further in cardiogenic shock. With rising costs and resources utilization, future research should focus on the impact of ECMO use on survival and on outcomes of patients with critical illnesses including but not limited to cardiogenic shock.
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Additional File 1:A list of Equivalent ICD-9 CM codes and variable classification. (DOCX 106 kb)

AHRQ

:   Agency for Healthcare Research and Quality

CCS

:   Clinical Classifications Software

CI

:   confidence intervals

CPR

:   Cardiopulmonary Resuscitation

ECLS

:   extracorporeal life support

ECMO

:   Extracorporeal membrane oxygenation

ED

:   emergency department

ELSORIR

:   Extracorporeal Life Support Organization Registry International Report

HCUP

:   Healthcare Cost and Utilization Project

IABP

:   include intra-aortic balloon pumps

ICD

:   International Classification of Diseases

IRB

:   Institutional Review Board

LOS

:   length of stay

LVADs

:   LV assist devices

NEDS

:   Nationwide Emergency Department Sample

VA

:   veno-arterial

VV

:   veno-venous
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